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Abstract
Background: NSCLC exhibits considerable heterogeneity in its sensitivity to chemotherapy and similar heterogeneity is noted
in vitro in a variety of model systems. This study has tested the hypothesis that the molecular basis of the observed in vitro
chemosensitivity of NSCLC lies within the known resistance mechanisms inherent to these patients' tumors.
Methods: The chemosensitivity of a series of 49 NSCLC tumors was assessed using the ATP-based tumor chemosensitivity
assay (ATP-TCA) and compared with quantitative expression of resistance genes measured by RT-PCR in a Taqman Array™
following extraction of RNA from formalin-fixed paraffin-embedded (FFPE) tissue.
Results: There was considerable heterogeneity between tumors within the ATP-TCA, and while this showed no direct
correlation with individual gene expression, there was strong correlation of multi-gene signatures for many of the single agents
and combinations tested. For instance, docetaxel activity showed some dependence on the expression of drug pumps, while
cisplatin activity showed some dependence on DNA repair enzyme expression. Activity of both drugs was influenced more
strongly still by the expression of anti- and pro-apoptotic genes by the tumor for both docetaxel and cisplatin. The doublet
combinations of cisplatin with gemcitabine and cisplatin with docetaxel showed gene expression signatures incorporating
resistance mechanisms for both agents.
Conclusion: Genes predicted to be involved in known mechanisms drug sensitivity and resistance correlate well with in vitro
chemosensitivity and may allow the definition of predictive signatures to guide individualized chemotherapy in lung cancer.
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Background
The variable response to chemotherapy with platinum
containing regimens in NSCLC is well recognized clini-
cally. Patients crossing from one regimen to the alternate
in clinical trials commonly show responses [1], suggesting
that it might be possible to optimize therapy for individ-
ual patients if it was also possible to determine which reg-
imen would be most effective. We and others have used
cellular tumor response assays to show similar heteroge-
neity in NSCLC [2-5], and data from other tumor types
such as ovarian cancer suggests that these tests correlate
relatively well with outcome [6,7], despite the rapid devel-
opment of resistance in many patients. However, such
tests using primary tumour-derived cells are time-con-
suming to perform and need a large amount of tumor tis-
sue, far more than it is generally feasible to obtain by
bronchoscopic or needle biopsy in most lung cancer
patients. This means that there is currently no direct corre-
lation of clinical outcomes with ATP-based tumor chemo-
sensitivity assay (ATP-TCA) results in lung cancer, but
there is good evidence to suggest that low passage cell line
models or primary tumour-derived cells (as used here) are
more reliable predictors of chemosensitivity than cell
lines [8].
It has long been a goal of cancer research to produce pre-
dictive molecular assays capable of widespread use. Single
genes are rarely useful, unless they happen to be the tar-
gets of the drugs concerned, but until recently it has been
difficult to produce predictive multigene signatures. In
practice, there are two possible approaches to the genera-
tion of multigene signatures for predictive chemosensitiv-
ity testing. The first is to screen very large numbers of
genes using hybridization arrays to generate signatures
that correlate with clinical outcome [9]. The second
approach is hypothesis-driven, using current knowledge
of the pathways involved in resistance and sensitivity to
individual drugs to generate sets of candidate genes likely
to be predictive [10]. We have taken the latter approach
and have designed genesets for chemosensitivity predic-
tion based on published information and previous stud-
ies. To test this, we have examined their correlation with
in vitro chemosensitivity data which allows multiple sin-
gle agents and combinations to be studied, something
that would clearly be impossible in patients.
In, the UK cisplatin-containing regimens are recom-
mended for primary chemotherapy of inoperable NSCLC,
and at the time we started this study, pemetrexed was not
available [11,12]. Of these, the most commonly used in
the UK are cisplatin with gemcitabine and cisplatin with
docetaxel. Docetaxel is also used as a single agent for
patients with reduced tolerance to chemotherapy, post-
surgery or on relapse. Patients that respond to one of these
regimens may respond to another: such crossover effects
provide evidence of heterogeneity of chemosensitivity in
NSCLC. Not all NSCLC patients will benefit from the
same treatment, and the molecular mechanisms involved
are still largely unknown. This study has tested the
hypothesis that the molecular basis of this difference lies
within the known resistance mechanisms inherent to
these patients' tumors. The resistance to anti-cancer drugs
involves many mechanisms [13,14], though those mech-
anisms involved for cisplatin, gemcitabine and taxane
resistance have been extensively studied across a wide
range of tumors.
Studies of cisplatin resistance in lung cancer are relatively
rare, though some data exist. For example increased
expression of the DNA repair enzyme ERCC1 has been
associated with worse outcome in NSCLC patients treated
with cisplatin-based chemotherapy [15], and has now
been used with some success to predict response to plati-
num-based chemotherapy [16], though it is unlikely that
single markers will be sufficient. The consensus seems to
be that cisplatin resistance mechanisms include decreased
drug accumulation, enhanced detoxification, and
increased DNA repair efficiency [13]. The one exception to
this is the presence of mismatch repair defects, which par-
adoxically increase the toxicity of cisplatin in many tumor
types [17-19]. Most membrane transporters, such as p-
glycoprotein (MDR1) are not involved in cisplatin resist-
ance, but the Copper-transporting ATPase (ATP7B) has
been implicated in a number of studies [20]. Detoxifica-
tion of cisplatin includes gluthione conjugation, and glu-
tathione S-transferase (GSTπ) has been implicated, as
have two members of the multidrug resistance related
protein family, MRP1 and MRP3, which are required to
transport conjugated xenobiotics [21]. Repair of plati-
nated DNA is primarily by nucleotide excision repair [22].
Expression of XPA,  XPG,  XPF,  ERCC1  and  ERCC2  are
apparently involved, but the relative importance of each
in this process is uncertain. In addition, the influence of
apoptosis related genes has been implicated in resistance
to cisplatin, particularly those such as BCL2  and SUR-
VIVIN which inhibit apoptosis [14,23].
A number of studies of potential gemcitabine resistance
mechanisms have been performed in lung cancer using
PCR or immunohistochemical methods. Multiple mem-
brane transporters, target enzymes, enzymes involved in
the metabolism of gemcitabine and alterations in the
apoptotic pathways have been implicated in sensitivity
and resistance to this drug in a variety of human tumor
types [24]. To date, there is evidence that several genes
involved in gemcitabine metabolism, particularly human
equilibrative nucleoside transporter 1 (hENT1) and
cytosolic 5'-nucleotidase type II (cN-II), are involved in
NSCLC resistance [25]. Resistance has also been linked to
the expression of DNA repair genes, particularly ERCC1,BMC Cancer 2009, 9:300 http://www.biomedcentral.com/1471-2407/9/300
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ribonucleotide reductase subunits 1 and 2 (RRM1  and
RRM2) [26], though immunohistochemical expression of
these proteins, RAD51 or BRCA1 could not be shown to
have an effect [27]. Recently, multidrug resistance associ-
ated protein 5 (MRP5), a membrane located pump, has
also been implicated in gemcitabine drug resistance [28].
The taxanes stablise microtubules and prevent their turn-
over, leading to apoptosis in many rapidly dividing cell
lines and some tumors. However, they are susceptible to
xenobiotic pump mechanisms, including P-glycoprotein
(MDR1), MRP, breast cancer related protein (BCRP) and
major vault protein (MVP). There has been relatively little
work on the ability of cells to resist the action of taxanes
based on resistance to apoptosis, but several studies sug-
gest that this is likely to be of importance [4,29,30].
It is generally assumed that the same resistance mecha-
nisms used by cells to circumvent single agent activity will
also be used against combinations of these drugs. There
are few mechanistic studies of resistance to platinum with
gemcitabine, or platinum with taxane to confirm or refute
this supposition. However, one study by Smith et al. [31]
in a series of endometrial cell lines suggested that GSTπ,
MSH2, P53, and ERCC1 may be involved, confirming ear-
lier single agent data implicating these mechanisms [13].
In addition, combining ERCC1  and  RRM1  has been
shown to have predictive efficacy for the combination of
platinum and gemcitabine [32].
The current study has tested the hypothesis that the
molecular basis of the observed difference in sensitivity in
vitro between primary tumor-derived cells in the ATP-TCA
lies within the known resistance mechanisms inherent to
these patients' tumor cells. The mechanisms of cellular
(i.e. non-pharmacokinetic) resistance to chemotherapy
include: down-regulation of target expression, drug
metabolism, membrane-located xenobiotic pumps,
altered susceptibility to apoptosis, and altered growth/cell
cycle or differentiation. Knowledge of these pathways ena-
bled the design of a Taqman Array microfluidic qRT-PCR
card to include 92 genes known or hypothesized to be
involved in drug resistance/sensitivity to cytotoxic agents,
including those described above (table 1). The Chemo-
sensitivity Gene Expression Array (CGEA-1, CanTech Ltd,
Portsmouth, UK) also included four housekeeping genes
to allow standardisation of the results for comparison of
individual tumor data. The CGEA is not comprehensive,
but has enabled us to establish the degree to which in vitro
sensitivity data correlate with gene expression data to
determine the likely contribution of individual genes to
drug sensitivity and resistance in NSCLC.
Methods
In this study we have used quantitative Reverse Tran-
scriptase Polymerase Chain Reaction (qRT-PCR) to exam-
ine the expression of several transporter and metabolism-
related genes previously shown by ourselves and others
(see above) to be involved in resistance to chemotherapy
with cisplatin, gemcitabine or taxanes in NSCLC. In addi-
tion we have examined several other mechanisms likely to
influence the effectiveness of chemotherapy which have
been less commonly studied. The RT-PCR expression pro-
files obtained from stored formalin-fixed paraffin-embed-
ded tissue have been compared with quantitative in vitro
chemosensitivity data obtained for the same tumors using
the ATP-based chemosensitivity assay (ATP-TCA).
Patients and Samples
A total of 62 specimens were obtained from surgical resec-
tions of NSCLC tumors from patients with a median age
of 69 years, range 54 – 87 years. There were 35 males and
27 females. Of these, 49 fresh samples proved suitable for
ATP-TCA. All cases had formalin-fixed paraffin-embedded
(FFPE) material taken for diagnostic histology, and gave
written informed consent for the study, which received
multicentre research ethics committee approval. The FFPE
blocks subsequently provided a source of material for
qRT-PCR. The breakdown by histological tumor type is
given in table 2.
ATP-TCA
In all cases, ATP-TCA data was obtained as previously
published [33,34]. Briefly, samples were transported to
the laboratory in 25 ml specimen bottles containing
cooled transport medium consisting of DMEM (Sigma,
Poole, Dorset, UK) with added antibiotics. Tumor cells
were obtained by enzymatic dissociation, washed in a
serum-free complete assay medium (CAM; DCS, Ham-
burg, Germany), and purified by density centrifugation to
remove debris. The cells were washed and resuspended in
CAM for plating in 96 well polypropylene plates at 20,000
cells per well with six dilutions of four drugs or combina-
tions tested in triplicate with two rows of medium only
and maximum inhibitor controls. At least 10% neoplastic
cells for successful ATP-TCA. The drug concentrations
used are given in table 3. The plates were incubated for six
days at 37°C with 5% CO2, and the remaining ATP
extracted with tumor cell extraction reagent (TCER; DCS).
Aliquots of the extract were transferred to a white 96 well
polystyrene plate to which an equal amount of luciferin-
luciferase was added. The resulting luminescence was read
in a luminometer (MPLX, Berthold Diagnostic Systems,
Germany) and the data transferred to an Excel (Microsoft)
spreadsheet for analysis. The results were expressed as the
percentage inhibition at each concentration tested, and a
summary index representing the sum of the surviving frac-
t i o n  o f  c e l l s  a t  e a c h  d i l u t i o n  t e s t e d  a s  6 0 0 -BMC Cancer 2009, 9:300 http://www.biomedcentral.com/1471-2407/9/300
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Table 1: Genes included on Taqman array, classified by their major contribution to drug resistance mechanisms.
Apoptosis DNA repair Proliferation Pumps/Detox
AKT ATM APC C-term ATP7B
APAF1 BRCA1 APC N-term BCRP
BAD ERCC1 β-TUBULIN III CES1
BAX ERCC2 COX2 CES2
BCL2 GTF2H2 EGFR cN II
BCL-x(L) MGMT HER2 DPD
BID MLH1 HER3 FPGS
c-FLIP MSH2 HER4 γ H2AX
FAS MSH6 HIF1A GCLC
FASL RAD51 KI67 GCLM
HSP60 TOPO I P16 GSTπ
HSP70 TOPO IIa P21 hENT1
HSP90 TOPO IIb P27 hENT2
IAP2 XPA P53 MDR1
IGF1 XRCC1 VEGF MRP1
IGF1R XRCC5 MRP2
IGF2 XRCC6 MRP3
IGF2R MRP4
IGFBP1 MRP5
IGFBP2 MRP6
MCJ MRP8
MCL1 MTII
mTOR MVP
NFkB House-keeping gene OPRT
PIK3CA 18S RRM1
PTEN HPRT SOD1
STAT3 PBGD TAP1BMC Cancer 2009, 9:300 http://www.biomedcentral.com/1471-2407/9/300
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Sum(Inh200....Inh6.25) [35], where 0 equals complete
inhibition and 600 equals no effect.
Extraction of RNA from FFPE tumor tissue
Eight 10 μm curl sections were cut from formalin-fixed
paraffin-processed blocks of lung including at least 75%
tumor tissue, placed in a 1.5 ml microcentrifuge tube and
heated at 70°C in a Stuart SBH200D heating block for 20
min to allow excess paraffin wax to be removed from the
tissue using a sterile fine tip plastic pasteur pipette. Exper-
iments with lung tissue only showed that this was unlikely
to interfere with the assay (data not shown). Pre-warmed
xylene (1 ml) was then added to the tube and heated at
50°C for 10 min. The microfuge tube was then removed
from the heating block, at centrifuged at 12,000 × g for 2
min in a Sanyo MSE Microcentaur microcentrifuge. Waste
xylene was then removed by pipette and the xylene wash
was repeated twice more. After the final wash the tissue
had uncurled.
Residual xylene was removed by the addition of 1.0 ml of
100% ethanol to the dewaxed tissue sections, which was
allowed to stand for 10 min at room temperature. The tis-
sue was then centrifuged 12,000 × g for 5 min and the eth-
anol removed by pipette, and the process repeated once
more with 100% ethanol. The tissue was then rehydrated
with 1.0 ml 90% ethanol, for 5 min and finally washed in
1.0 ml 70% ethanol for 5 min. The microfuge lids were
then opened to allow the ethanol to evaporate completely
prior to protease digestion.
Protease digestion was performed by use of a Recoverall
kit™ (Applied Biosystems, AM1975). Digestion buffer
(400 μl) and protease (4 μl) were added to each tissue
sample and incubated for 3 hours at 50°C, with occa-
sional flicking of the tube to assist uniform digestion. If
the tissue was not digested to a clear solution, a further 60
minute incubation was performed, following which 480
μl of the Ambion RecoverAll™ Isolation Additive was
added to the microfuge tube, which was then vortex
mixed for 20 seconds and allowed to stand for 15 min at
room temperature. The tubes were pulse spun in a micro-
fuge at 12,000 × g for 30 seconds before opening to ensure
that the liquid was at the bottom of the tube and the lysate
was then passed ≥ 5 times through a 0.8 mm needle (21
gauge) fitted to a 1 ml sterile polypropylene syringe to
break up any large pieces of tissue. Two 240 μl aliquots of
the resulting lysate were then stored at -20°C for RNA
extraction.
RNA extraction was performed using the Recoverall kit™.
Briefly, the sample lysate was slow thawed at 4°C with
gentle vortexing before the addition of 550 μl of 100%
ethanol added to each tube. Filter cartridges for RNA iso-
lation were inserted in collection tubes, and 700 μl of the
lysate/ethanol mix pipetted onto the centre of each car-
tridge. The cartridges were centrifuged at 10,000 × g for 60
seconds, the flow through discarded and the filter car-
tridge re-inserted into the same collection tube. This was
repeated twice more until all the lysate had been proc-
essed for each sample. The cartridges were washed accord-
ing to the manufacturer's instructions and the flow
through discarded. DNase treatment of the immobilized
nucleic acids was performed by the addition of 60 μl of
DNase mix to the centre of each Filter Cartridge, incuba-
tion for 30 min at room temperature, followed by further
washes. Finally, the filter cartridge was placed into a fresh
collection tube and 30 μl of heated (95°C) nuclease free
water placed into the centre of the filter. Following incu-
bation at room temperature for 60 seconds, the filters
were microfuged for 60 seconds at 13,000 rpm (13,000 ×
g). This was repeated to give a final volume of 60 μl total
SURVIVIN SDHA TAP2
XIAP TBP TAP4
Table 1: Genes included on Taqman array, classified by their major contribution to drug resistance mechanisms. (Continued)
Table 2: Patient histological classification in the initial surgical 
series used to generate signatures.
Description Number
Squamous cell carcinoma 21
Adenocarcinoma 20
Neuroendocrine NSCLC 3
Poorly differentiated carcinoma 5
Total on study: 49
Excluded:
- Metastatic 4
- Carcinoid 1
- No cells in sample 7
- Contamination of sample/culture 2
- Failure of assay 1
Total 64BMC Cancer 2009, 9:300 http://www.biomedcentral.com/1471-2407/9/300
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RNA. Purity and quantity was checked spectrophotometry
at 260 nm and 280 nm by placing 1.3 μl of eluate on the
sampling pedestal of a scanning NanoDrop ND-1000™
spectrophotometer. Aliquots of each sample were stored
at -80°C or reverse transcribed to produce cDNA in a two
step RT-PCR reaction.
Two-step RT-PCR
Reverse transcription was performed using an ABI High-
Capacity cDNA Archive Kit (cat 4322171) according to
the manufacturer's instructions. Briefly, an aliquot of 75
μl master mix was added to a 0.2 ml PCR tube to which an
equal volume of purified RNA diluted in nuclease free
water was added. For RT negative wells, a 15 μl master mix
was prepared where the multiscibe RT volume was
replaced with nuclease-free water. To this was added 15 μl
of diluted RNA in nuclease-free water. The final RNA con-
centration in the RT mix was 50 ng/μl. The tubes were kept
in a chilled cooling block until ready to load into the ther-
mal cycler (Hybaid Omn-E). Cycling conditions were step
1, 25°C × 10 min, step 2, 37°C for 120 min. After removal
from the thermal cycler, the tubes were pulse spun in a
microfuge at 12,000 × g for 30 seconds and stored over-
night at 4°C or used immediately. cDNA content was
measured using a NanoDrop™ spectrophotometer prior to
use in a 'sighting shot' PCR reaction which was performed
for all samples to ensure housekeeping gene expression
and to confirm that the cDNA was suitable for Taqman
Array evaluation.
Pre-Taqman array 'sighting shot' evaluation of newly pre-
pared cDNA was performed by SYBR green PCR for HMBS
(PBGD) by adding a 5 μl volumes of 10 μg and 2.5 μg
cDNA into one of two wells of a polystyrene PCR plate,
each well of which contained 20 μl of master mix (diluted
SYBR Green ×2 master mix; Sigma Aldrich S-4438), in
nuclease-free water to which primers and MgCl2 had been
added. RT negative controls were also included for each
sample. PCR was run for 40 cycles in a BioRad i-Cycler
and the results transferred to a Microsoft Excel spread-
sheet for analysis. Samples with cycle thresholds for detec-
tion (Cts) below 35 and undetectable results from the RT
negative control were deemed evaluable for use in a Taq-
man array.
GCEA Taqman arrays were run according to the manufac-
turer's instructions. Each sample was made up with Taq-
man ×2 Universal Master Mix and mixed with an equal
volume of cDNA to give a final concentration of 300 ng/
μl suitable for the small volume dry PCR Taqman array
wells. All four samples were then each pipetted into two
ports (100 μl per port) of the 384 well card, for the 96
genes arrayed.
The loaded CGEA Taqman array was then placed, port
upwards, into a balanced centrifuge (type, address) and
spun at 380 × g to fill the card. This was checked and the
card spun again at 380 × g to remove any air bubbles. The
card was then placed in a Taqman array slide sealer,
sealed, and the loading ports cut from the card before it
was loaded into an AB 7900HT thermal cycler. PCR was
performed for 90 min with the following conditions:
AmpErase UNG Activation for 2 min at 50°C; AmpliTaq
Gold DNA Polymerase Activation for 10 min at 94.5°C;
followed by 40 cycles each of Melt Anneal/Extend for 30
sec at 97°C and 1 min at 59.7°C.
The 'Auto Threshold Cycle' function was performed at the
end of the run and resulting Ct data from the CGEA Taq-
man array card was transferred to a Microsoft Excel
spreadsheet, controls checked, and the data transferred to
a Microsoft Access database for further analysis.
During the course of the study three standard curve cards
were performed using the same cDNA sample with the
following final concentrations of cDNA 1100 ng/μl, 300
Table 3: Drug list for ATP-TCA with manufacturer, given with the 100% test drug concentration (TDC) used in the assay, and the 
number of tumors tested. 
Drug or combination Manufacturer TDC (μM) Number tested
Docetaxel Sanofi-Aventis 3.00 43
Cisplatin Bristol-Myers-Squibb 10.00 41
Gemcitabine Eli Lilly 40.04 39
Cisplatin with Gemcitabine As single agents As single agents 38
Docetaxel with Cisplatin As single agents As single agents 22
Docetaxel with Gemcitabine As single agents As single agents 21
Some tumors had too few cells for all agents/combinations to be tested.BMC Cancer 2009, 9:300 http://www.biomedcentral.com/1471-2407/9/300
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ng/μl, 150 ng/μl and 75 ng/μl. On examining each of the
multiple targets standard curves and primer/probe effi-
ciencies, the optimal final concentration of cDNA was
deemed to be 300 ng/μl, and used for all samples. In addi-
tion, two replicate cards were run with the same cDNA
samples, using three replicates at a final concentration
cDNA of 300 ng/μl, and one no template control (NTC;
nuclease-free water) on each card.
Ct values were standardised by reference to HMBS
(PBGD), the least variable housekeeping gene of the four
present on the array, which was detected at cycle 29, to
avoid errors due to differences in efficiency between the
HK and test genes which were present from cycle 27 – 35
in most cases. The standard method of analysis (deltaCt)
was inappropriate for linear regression as it skews the data
obtained, and therefore normalised the data by logarith-
mic transformation. A logarithmic gene expression ratio
(GER) was calculated as ln(2-Ct [test]/2-Ct [PBGD]) and used
for comparison with ATP-TCA data by multiple linear
regression using SPSS ver 14.0 and Analyse-It software.
Data Analysis
Sample size calculations for the in vitro chemosensitivity
correlation with the CGEA data were performed using an
on-line multiple regression sample size calculator http://
www.danielsoper.com/statcalc based on analysis of up to
25 variables (predictors) and an anticipated r-squared of
0.5 with 80% power and alpha 0.05, giving a required
sample size of 36 patients for each drug or combination
measured.
The data from ATP-TCA, and qRT-PCR studies were col-
lected into an Access database (Microsoft), from which
descriptive statistics were generated. Statistical compari-
son of ATP-TCA results for individual drugs (continuous
dependent variable) with CGEA gene expression data was
performed by multiple linear regression with forward
selection of variables using SPSS ver 14.0 (SPSS Inc, Chi-
cago, USA). For each variable, inclusion was dependent
upon a probability of F > 0.1, i.e. the threshold for inclu-
sion of a gene into the forward linear regression model
within SPSS, based on initial assessment of the most
appropriate model size. The PRESS (prediction residual
sum of squares) graphs shown use an adjusted regression
method employed to prevent overfitting, as a 'leave one
out method'. No intercept was term was included, and
genes were added by forward regression according to their
univariate correlations following entry of each gene. The
number of genes accepted into each model was based on
initial assessment of the most appropriate model size
using Akaike Information Criterion versus model size
(data not shown). The Akaike Information Criterion
(AIC) is a function of model error and size which penal-
ises large models, and the lowest number is regarded as
best.
Results
ATP-TCA
There were sufficient cells for testing of one drug or more,
with evaluable results, in 52 specimens with a diagnosis of
NSCLC following surgery and sufficient cells for testing.
Three specimens failed to produce results in the assay: one
due to low ATP counts at the end of the assay, while the
other cultures became infected, probably due to low level
contamination within the samples.
The results from the 49 samples with evaluable ATP-TCA
data show considerable heterogeneity of chemosensitivity
between tumors (figure 1) tested with single agents and
combinations. Cisplatin is usually more active than
docetaxel, with a steeper concentration-inhibition curve
(figure 1). Of the combinations tested, cisplatin with gem-
citabine was the most active in this series of experiments
(figure 1), and proved more effective than cisplatin with
docetaxel in the 21 tumors tested with both combinations
(Wilcoxon, p < 0.0001). Several experimental regimens
were tested. Comparison of the largest histological sub-
groups of NSCLC (i.e. those showing squamous or glan-
dular differentiation) showed no difference in the effect of
treatment, and no gender effects were noted on sensitivity
to cisplatin, docetaxel or doxorubicin.
The ATP-TCA IndexSUM is a natural logarithmic index,
ranging from 0 – 600 for inhibition, with zero corre-
sponding to complete cell kill, and 600 equating to no
effect. Examination of frequency histograms and Index-
SUM data (figure 2, table 4) for each of the drugs tested
shows considerable heterogeneity of chemosensitivity
between individual tumors for all drugs tested, with the
greatest activity (i.e. lowest IndexSUM) for cisplatin with
gemcitabine, and cisplatin with docetaxel. The single
agents alone are relatively inactive (figure 2) in compari-
son with the combinations.
All six agents were tested in 24 tumours. Comparison of
these paired results by IndexSUM (figure 3) shows the
greater sensitivity of NSCLC to gemicitabine with respect
to cisplatin (p < 0.001), and docetaxel (p < 0.001). Cispl-
atin was marginally more active than docetaxel (p <
0.022). However, in 3/24 tumors, cisplatin was the most
active agent, while in 3/24 tumors docetaxel was the most
active agent, and in 18/24 tumors gemcitabine was the
most active agent. Comparison of the three combinations
tested showed that cisplatin + gemcitabine was more
active than cisplatin + docetaxel (p < 0.001), and
docetaxel + gemcitabine (p < 0.001) though the of the two
docetaxel containing regimens docetaxel ± gemcitabine
was the more active (p < 0.007). However, there was someBMC Cancer 2009, 9:300 http://www.biomedcentral.com/1471-2407/9/300
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Heterogeneity of chemosensitivity for (a) docetaxel (b) cisplatin, (c) cisplatin with docetaxel, (d) cisplatin with gemcitabine, and  (e) docetaxel with gemcitabine, (f) gemcitabine Figure 1
Heterogeneity of chemosensitivity for (a) docetaxel (b) cisplatin, (c) cisplatin with docetaxel, (d) cisplatin with 
gemcitabine, and (e) docetaxel with gemcitabine, (f) gemcitabine. Each line represents a different tumor tested at six 
concentrations.
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ATP-TCA results expressed as histograms for IndexSUM for the drugs and combinations most commonly used in NSCLC Figure 2
ATP-TCA results expressed as histograms for IndexSUM for the drugs and combinations most commonly 
used in NSCLC. (a) cisplatin (b) gemcitabine (c) cisplatin with gemcitabine (d) docetaxel, (e) docetaxel with cisplatin, (f) 
docetaxel with gemcitabine.
 
(a)       (b) 
 
700 600 500 400 300 200 100
INDEX
14
12
10
8
6
4
2
0
F
r
e
q
u
e
n
c
y
Mean =446.44
Std. Dev. =111.276
N =41
Histogram
1000 800 600 400 200 0
INDEX
12.5
10.0
7.5
5.0
2.5
0.0
F
r
e
q
u
e
n
c
y
Mean =381.82
Std. Dev. =140.615
N =39
Histogram  
 
 
 
 
 
 
 
 
 
 
 
 
 
(c)       (d) 
 
400 200 0
INDEX
10
8
6
4
2
0
F
r
e
q
u
e
n
c
y
Mean =206.21
Std. Dev. =107.444
N =38
Histogram
800 700 600 500 400 300 200 100
INDEX
14
12
10
8
6
4
2
0
F
r
e
q
u
e
n
c
y
Mean =505.81
Std. Dev. =134.72
N =42
Histogram  
 
 
 
 
 
 
 
 
 
 
 
 
 
(e)       (f) 
 
500 450 400 350 300 250 200
INDEX
8
6
4
2
0
F
r
e
q
u
e
n
c
y
Mean =316.3
Std. Dev. =63.667
N =23
Histogram
600 400 200
INDEX
8
6
4
2
0
F
r
e
q
u
e
n
c
y
Mean =378.41
Std. Dev. =71.163
N =22
Histogram  
 
 
 
 
 
 
 
 
 
 
 
 BMC Cancer 2009, 9:300 http://www.biomedcentral.com/1471-2407/9/300
Page 10 of 17
(page number not for citation purposes)
heterogeneity, though in most (20/24) tumors cisplatin +
gemcitabine was the most active combination, in 4/24
tumors docetaxel + gemcitabine was the most active.
Either were always better than cisplatin + docetaxel in this
series (figure 3, table 4). ATP-TCA data can be used to gen-
erate data on additive or synergistic effects between drugs,
but this analysis has not been preformed as it is of limited
relevance to this paper.
qRT-PCR
Despite the use of FFPE tissue, all samples were regarded
as evaluable on the basis of the housekeeping gene Ct lev-
els (i.e. PBGD Ct > 35 cycles). Variation in HK gene levels
was limited, with a normal distribution of Ct levels
(PBGD, mean 29.301 (95% CI 28.630 – 29.971). Ct levels
within the detectable range were present for most of the
genes present on the Taqman array [see Additional file 1],
though some were more rarely expressed than others, and
NTC remained undetectable throughout the study.
The two replicate plates showed an intra-assay variation
(CoV) of 0.32% and 0.07% on Ct values from the same
sample, while the same sample tested five times in differ-
ent plates showed an inter-assay variation (CoV) of 0.51%
for HMBS. Two dilution plates were run during the series
of Taqman arrays to assess the efficiency of the genes
included on the plate. These results show 99% efficiency
for HMBS.
Correlation of mechanisms with ATP-TCA data
In general, comparison with genesets linked to particular
resistance mechanisms showed good correlation with
drugs susceptible to these mechanisms in multiple regres-
sion analysis (figure 4), provided that the drugs were
active and showed heterogeneity of chemosensitivity with
a spread of sensitive and resistant tumors. Although the
genes chosen were not a naïve dataset, as all had been
related to drug resistance or sensitivity, for the purpose of
this report the SPSS analysis included all genes present on
the card. Forward multiple regression models were identi-
fied for each drug or combination included in the study.
The genes involved are shown in table 5, in order of great-
est contribution to the model, and the coefficients for
each in table 6.
Cisplatin activity showed strong correlation with resist-
ance gene expression, particularly those genes involved in
DNA repair (e.g. ATM kinase and GTF2H2) and apoptosis
(e.g. IAP2, BID, MCJ, P53, mTOR, and MCL1). Few drug
pumps were present in the model, though MRP5 and MVP
were present, as well as two nucleotide metabolism genes,
TS and FPGS. Docetaxel activity showed greater correla-
tion with drug pump expression and detoxification mech-
anisms, with no relationship to DNA repair. Docetaxel
showed little activity as a single agent, but was correlated
with two MDR-related pumps (MRP5 and MRP8), and
with  GSTπ  expression, as well as IGF binding protein
(IGFBP). Forced addition of β-TUBULIN III to the final
model added no benefit to the model. Few of the genes
thought to be involved in gemcitabine expression were
present on the card, and only MRP4 was selected by statis-
tical analysis, though this had a very low level of correla-
tion with gemcitabine sensitivity (figure 4).
Table 4: Data for each drug and combination tested, showing median and interquartile range (in brackets) for IC50, IC90 (both 
expressed as % TDC) and IndexSUM. 
Drug/Combination IC90 (%TDC) IC50 (%TDC) IndexSUM Number with > 95% inhibition
Docetaxel 433
297 – 778.5
246
71 – 438
523
419 – 591
0/43
Cisplatin 229
204 – 278
95
71 – 156
466
378 – 513
0/41
Gemcitabine 300
242 – 383
82
22 – 213
378
293 – 446
0/39
Cisplatin with Gemcitabine 80
46 – 143
13
8 – 23
186
136 – 231
19/38
Docetaxel with Cisplatin 213
203 – 231
75
59 – 93
378
339 – 405
0/22
Docetaxel with Gemcitabine 242
224 – 267
45
37 – 78
310
290 – 370
0/21
The final column shows the number of tumors tested and those achieving 95% inhibition at the 100% TDC of those tested for each drug or 
combination.BMC Cancer 2009, 9:300 http://www.biomedcentral.com/1471-2407/9/300
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Cross resistance in the ATP-TCA between (a) drugs and (b) combinations, expressed as IndexSUM Figure 3
Cross resistance in the ATP-TCA between (a) drugs and (b) combinations, expressed as IndexSUM.
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Multiple linear regression analysis (PRESS) by unsupervised forward selection for (a) cisplatin; (b) gemcitabine; (c) cisplatin with  gemcitabine; (d) docetaxel; (e) docetaxel with cisplatin Figure 4
Multiple linear regression analysis (PRESS) by unsupervised forward selection for (a) cisplatin; (b) gemcitabine; 
(c) cisplatin with gemcitabine; (d) docetaxel; (e) docetaxel with cisplatin. No correlation was obtained for docetaxel 
with gemcitabine.
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Greater levels of correlation were found between gene
expression and chemosensitivity to combinations. Cispla-
tin with gemcitabine showed excellent correlation with a
model containing 22 genes, including a number of DNA
repair and apoptosis genes, though no less than 4 drug
pumps are also included in this model. There were fewer
observations for cisplatin with docetaxel due to the order
in which drugs were tested in the ATP-TCA: some tumors
contained too few cells to test all drugs. Both lists include
a number of genes involved in apoptosis, as well as GSTπ
and drug pump molecules, together with a several genes
involved in DNA repair. It is noted that the first two genes
in the cisplatin with docetaxel model are APAF1, involved
in apoptosis, and MLH1, a mismatch repair gene.
No tumor type-specific differences were found between
adenocarcinomas and squamous cell carcinomas for any
of the drugs studied.
Discussion
Use of the ATP-TCA has allowed us to examine both single
and combination effects for the same tumors, and for the
first time to compare chemosensitivity data with the
expression of a large number of potential resistance mech-
anisms using a robust qRT-PCR approach with mRNA
obtained from FFPE biopsy material. While the ATP-TCA
requires large surgical biopsy specimens, the qRT-PCR
method can be performed with a few nanograms of RNA
extracted from FFPE tissue. Similar RT-PCR results to these
can be produced from the much smaller samples obtained
by bronchoscopic or needle biopsy (Gabriel et al., unpub-
lished). If this approach proves to be related to clinical
outcome, it may be possible to design tests to predict the
efficacy of the two main chemotherapy regimens currently
in use for NSCLC treatment and to optimize patient treat-
ment on this basis.
The comparison of quantitative data from the ATP-TCA
(CoV 15%) with that from qRT-PCR (CoV 2%) has the
advantage that relatively small numbers of tumors are
required to obtain data on the genes relevant to resistance
and sensitivity to drugs tested in the assay. This may prove
to be particularly useful to investigate the mechanisms of
sensitivity and resistance for drugs which are rarely used as
single agents in specific tumor types, and for new drugs
which have not yet entered the clinic. However, for single
agents, there is less sensitivity, and less variation between
patients in the ATP-TCA, and therefore lower levels of cor-
relation with gene expression were found for the single
agents.
The Taqman array card included all of the genes described
in the introduction to this paper, but was manufactured
before some more recent papers were published which
suggest that others may also be important. For instance,
for gemcitabine, other genes involved include human
concentrative nucleoside transporter (hCNT3), deoxyciti-
dine kinase (dCK), cytidine deaminase (CDA), Cytidine
deaminase (CDD) and 5'-nucleotidase (5NT) gene poly-
morphisms and CDD, 5NT, deoxycytidine kinase (DCK)
and MRP5 [28,36]. Further work is therefore required to
define genesets that might be clinically useful.
The genes identified in this study fall into several catego-
ries, linked with much studied mechanisms such as
metabolism within the cell, membrane drug pumps, and
DNA repair, but also with apoptosis, suggesting that the
general susceptibility of the cell to undergo this process
may be an important determinant of tumor chemosensi-
tivity, outweighing more specific mechanisms [14]. The
genes found to be important by unsupervised forward
selection multiple regression match well with those
thought to be important from previous studies in cell lines
and multiple tumor types. Other statistical methods have
been applied (data not shown), including analysis of
principal components, cluster analysis and supervised
regression models. All show a similar ability to derive
models which describe the data, and the importance of
genes related to particular resistance/sensitivity mecha-
nisms seem to hold up remarkably well. Inevitably there
are some discrepancies between the published literature
and our findings, but the number of tumors is as yet rela-
tively small and it is important not to read too much into
the individual genes within the models.
Most combinations used in lung cancer have been derived
empirically from phase II and phase III clinical trials.
However, synergy has been observed in cell lines between
cisplatin and several agents: notably taxanes and gemcit-
abine. The basis of this synergy is unclear for platinum
Table 5: Genes found to correlate in multivariate linear regression analysis using forward selection: model summaries.
Model R R2 Adj R2 Std. Error Significance
(ANOVA)
Cisplatin 0.965 0.931 0.892 36.976 0.001
Gemcitabine 0.277 0.076 0.051 136.326 0.093
Docetaxel 0.664 0.441 0.361 107.579 0.001
Cisplatin with Gemcitabine 0.997 0.995 0.987 12.565 0.001
Cisplatin with Docetaxel 0.959 0.92 0.885 23.375 0.001BMC Cancer 2009, 9:300 http://www.biomedcentral.com/1471-2407/9/300
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Table 6: Genes found to correlate in multivariate linear regression analysis using forward selection: coefficients for each gene included 
in the model by drug or combination tested.
Unstandardized Standardized t Collinearity Statistics
Gene B Std. Error Beta Lower Bound B Std. Error
Cisplatin
(Constant) 403.123 33.393 12.072
GTF2H2 64.781 16.558 0.573 3.912 0.129 7.725
IAP2 -153.15 16.813 -2.122 -9.109 0.051 19.571
MRP5 71.075 8.946 0.799 7.945 0.274 3.651
P53 -91.289 11.062 -0.63 -8.252 0.476 2.101
ATM kinase 105.764 14.77 1.494 7.161 0.064 15.71
FPGS 30.449 9.411 0.391 3.235 0.19 5.263
mTOR -14.902 14.509 -0.146 -1.027 0.137 7.273
TS 42.031 7.318 0.584 5.744 0.269 3.724
MCJ 92.954 14.616 0.908 6.36 0.136 7.355
BID -49.393 12.785 -0.402 -3.863 0.256 3.9
Topo I -72.192 17.437 -0.688 -4.14 0.1 9.957
Mcl-1 57.031 12.755 0.69 4.471 0.116 8.597
HER2 -12.172 5.364 -0.179 -2.269 0.448 2.233
MVP -30.265 13.535 -0.197 -2.236 0.357 2.805
Gemcitabine
(Constant) 338.553 35.306 9.589
MRP4 -28.047 16.241 -0.277 -1.727 1 1
Docetaxel
(Constant) 778.346 103.411 7.527
MRP5 62.715 14.617 0.623 4.291 0.757 1.322
GSTπ -77.649 24.429 -0.461 -3.179 0.76 1.316
IGFBP2 -25.582 12.653 -0.265 -2.022 0.933 1.072
IGFBP1 28.488 10.056 0.411 2.833 0.76 1.316
MRP8 -22.098 9.513 -0.333 -2.323 0.777 1.287
Cisplatin with Gemcitabine
(Constant) 350.892 41.063 8.545
BAX 51.989 11.961 0.273 4.346 0.094 10.64
HER3 -10.321 4.863 -0.098 -2.122 0.172 5.813
MRP3 -19.569 1.948 -0.371 -10.044 0.272 3.681
AKT -150.08 7.205 -1.064 -20.831 0.142 7.063
MRP8 26.222 2.484 0.45 10.556 0.203 4.915
MRP5 43.708 3.634 0.474 12.026 0.238 4.209
BCL-x(L) 178.422 11.378 1.177 15.682 0.066 15.23
EGFR -46.006 4.356 -0.47 -10.562 0.187 5.353
hENT2 32.558 4.365 0.427 7.458 0.113 8.855
XRCC5 90.76 6.702 0.547 13.543 0.227 4.412
IGFBP1 -5.027 2.315 -0.086 -2.171 0.235 4.26
cN II -73.932 9.164 -0.562 -8.067 0.076 13.146
HPRT 49.176 4.955 0.715 9.925 0.071 14.029
RRM1 -69.228 7.483 -0.63 -9.251 0.08 12.527
P16 7.663 2.017 0.146 3.798 0.251 3.989
TAP2 -43.744 6.008 -0.284 -7.281 0.243 4.115
MGMT 45.697 6.513 0.377 7.016 0.128 7.799
ATP7B -7.418 2.019 -0.14 -3.675 0.255 3.928
KI67 -8.882 2.763 -0.161 -3.215 0.147 6.807
TOPO IIa -6.788 1.708 -0.137 -3.973 0.311 3.218
BCRP 13.738 3.335 0.191 4.12 0.172 5.8
VEGF 12.683 5.573 0.098 2.276 0.199 5.034
Cisplatin with Docetaxel
(Constant) 178.403 46.289 3.854
APAF1 38.159 5.752 0.855 6.635 0.345 2.899
MLH1 -63.725 6.467 -1.339 -9.854 0.31 3.223BMC Cancer 2009, 9:300 http://www.biomedcentral.com/1471-2407/9/300
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with docetaxel, but is likely to be indirect as platinum is a
DNA-damaging agent, while taxanes stabilize microtu-
bules. In contrast, there several groups have shown that
gemcitabine can reverse resistance to cisplatin by its inhi-
bition of DNA repair [24,37]. Gemcitabine is only incor-
porated during DNA replication or repair. Since most
solid tumors have a relatively low S-phase fraction, single
agent gemcitabine has limited activity (though continu-
ous administration may be cytostatic [38]. Concomitant
administration of a DNA damaging agent, such as plati-
num, leading to upregulated DNA repair will have two
effects. Firstly, gemcitabine will be incorporated more
readily into DNA of non-dividing cells, and secondly, its
ability to inhibit DNA polymerase will tend to prevent
resistance to the DNA-damaging agent [39]. The effect on
DNA repair seems to occur at much lower concentrations
of gemcitabine than direct incorporation, suggesting that
there is no need to use high doses of gemcitabine in plat-
inum with gemcitabine combinations. This explains the
potency of this regimen in NSCLC, but clearly resistant
patients exist, and indeed some tumors in this study were
more sensitive to alternative regimens.
While reverse resistance can help to explain why there are
so few genes in common when cisplatin and gemcitibane
(MRP5, MCL1, MVP) and cisplatin and docetaxel (GSTπ,
MRP8,  FPGS,  P53,  DPD,  IAP2) are used together as
opposed to separately (Table 6), the number of extra
genes correlated when cisplatin is used in combination
with gemcitabine (n = 19) and docetaxel (n = 14) indi-
cates that there may be still unknown linkages and path-
ways between NSCLC-related genes that need further
exploration.
One of the main reasons behind our decision to study
NSCLC first was that there are two common types with
very different histopathology and oncogenesis. The find-
ing that there is no difference between the adenocarcino-
mas and squamous cell carcinomas in this series suggests
that resistance and sensitivity to cytotoxic agents, at least,
is determined by the gene expression profile of the cell for
a particular drug, and that tumor type is of lesser impor-
tance. This fits with current clinical practice in which
drugs such as cisplatin, docetaxel, and gemcitabine are
used for a wide range of different solid tumor types, albeit
with varying success.
Conclusion
In conclusion, the data presented here support the
hypothesis that the molecular basis of the observed differ-
ence in sensitivity between NSCLC tumors lies within the
known resistance mechanisms inherent to these patients'
tumors. It suggests that the Taqman array is ideally suited
to investigate the presence of these mechanisms in lung
tumors alongside cellular chemosensitivity testing with
individual drugs or combinations, and this may be of par-
ticular relevance to decision making during drug develop-
ment.
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